- TheStreet.com•19 days ago
David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.
- TheStreet.com•last month
Answering questions from the Biotech Mailbag on FLXN and SGYP.
- TheStreet.com•2 months ago
AstraZeneca shares, meanwhile, were less-than-moved by the news.
MDVN : Summary for Medivation, Inc. - Yahoo Finance
Medivation, Inc. (MDVN)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|